蛋白质亚单位
病毒学
生物
重组DNA
化学
dna疫苗
微生物学
抗原
HEK 293细胞
分子生物学
细胞培养
免疫系统
免疫
作者
Sun-Young Kim,Fengjia Chen,Woo‐Sik Kim,Hyun Jung Ji,Min-Kyu Kim,Hae Ran Park,Charles Euloge Lamien,Viskam Wijewardana,Kyung-Hyo Kim,Ki Bum Ahn,Ho Seong Seo
标识
DOI:10.1093/infdis/jiag131
摘要
Background Streptococcus suis (S. suis) is a zoonotic pathogen causing economic losses in the swine industry and severe human infections. High serotype variability and genomic diversity of S. suis hinder cross-protective vaccine development. Although advances in in silico prediction-driven antigen discovery have accelerated protein vaccine development, discrepancies between predicted immunogenicity and experimentally verified protection in animal models emphasize the need to integrate computational design with empirical validation. Methods Using an in silico design strategy, predicted T- and B-cell epitope-rich domains from S. suis antigens (HP0197, Fnbp, Sao, ScpB, and SLY) were assembled into a multimeric vaccine, ATOMSSUISpenta, optimized for predicted immunogenicity, solubility, and allergenicity. Vaccine efficacy was evaluated in mice through antibody profiling, cellular immunity analysis, and assessment of cross-serotype immunity. Results ATOMSSUISpenta elicited strong humoral responses against all component antigens. The vaccine also induced Th1- and Th17-type cellular responses, critical for opsonic and mucosal defense against S. suis. In addition, ATOMSSUISpenta conferred significant protection in a S. suis serotype 2 infection and induced opsonic antibodies against serotypes 4 and 9. Conclusions These findings highlight ATOMSSUISpenta as a subunit vaccine strategy with potential for broader protection and demonstrate the effectiveness of epitope-based multimeric design against antigenically diverse Gram-positive pathogens.
科研通智能强力驱动
Strongly Powered by AbleSci AI